Authors
Latest:
Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community CenterPanelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.
Latest:
Unmet Needs and Future Perspectives on Treating Patients With Multiple MyelomaConcluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardsConclusion of the discussion and award presentation.
Latest:
Hereditary Renal Tumor Syndromes and the Use of mTOR InhibitorsA 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Latest:
OncView™ Podcast: Updates in Therapies for Relapsed/Refractory Follicular LymphomaThis special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Best Practices for Boosting the Enrollment of Underserved Populations in Cancer Clinical TrialsCoral Omene, MD, PhD, and Mariam Eskander, MD, MPH, discuss how to continue engagement in clinical trial enrollment for underserved populations.
Latest:
Providing Supportive Care to Patients with NSCLCHelping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Latest:
The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant ChemotherapyExperts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Latest:
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision OncologyExplore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.
Latest:
Guiding Through Challenges: Insights for Caregivers of R/R MM PatientsUrsula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
Should Those with Non-Hodgkin Lymphoma Receive CAR T or Bispecifics?Although data for bispecific antibodies are maturing, CAR T-cell therapy has longer-term data that show prolonged and durable efficacy in LBCL.
Latest:
3 Things You Should Know About the Multimodal Treatment of SCLCHere are 3 things you should know about the multimodal treatment of patients with SCLC.
Latest:
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell LymphomasP. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Latest:
Future Directions in nccRCCPanelists discuss the ongoing challenges and progress in treating non–clear cell renal cell carcinoma (nccRCC), emphasizing the need for subtype-specific trials, mechanistically driven therapy, and international collaboration to move beyond data extrapolation from clear cell RCC (ccRCC) and toward truly evidence-based, personalized care.
Latest:
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research RecommendationsThis review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
